| |
original article |
Date |
Title |
Authors Max. 6 Authors |
| 1 |
[GO] |
2024―Apr―09 |
OpenSAFELY: The impact of COVID-19 on azathioprine, leflunomide and methotrexate monitoring, and factors associated with change in monitoring rate |
Andrew D. Brown, Louis Fisher, Helen J. Curtis, Milan Wiedemann, William J. Hulme, Victoria Speed, Lisa E. M. Hopcroft, Christine Cunningham, Ruth E. Costello, James B. Galloway, Mark D. Russell, Katie Bechman, Zeyneb Kurt, Richard Croker, Chris Wood, Alex J. Walker, Andrea L. Schaffer, Seb C. J. Bacon, Amir Mehrkar, George Hickman, Chris Bates, Jonathan Cockburn, John Parry, Frank Hester, Sam Harper, Ben Goldacre, Brian MacKenna |
| 2 |
[GO] |
2024―Mar―31 |
Impact of the early COVID-19 pandemic on adult mental health-related dispensed medications, hospitalizations and specialist outpatient visits in Norway and Sweden: Interrupted time series analysis |
David Moreno-Martos, Jing Zhao, Huiqi Li, Fredrik Nyberg, Ludvig Daae Bjørndal, Mohammadhossein Hajiebrahimi, Björn Wettermark, Mia Aakjær, Morten Andersen, Maurizio Sessa, Angela Lupattelli, Hedvig Nordeng, Daniel R. Morales |
| 3 |
[GO] |
2024―Feb―09 |
An artificial intelligence algorithm for co-clustering to help in pharmacovigilance before and during the COVID-19 pandemic |
Alexandre Destere, Giulia Marchello, Diane Merino, Nouha Ben Othman, Alexandre O. Gérard, Thibaud Lavrut, Delphine Viard, Fanny Rocher, Marco Corneli, Charles Bouveyron, Milou-Daniel Drici |
| 4 |
[GO] |
2023―Dec―30 |
Clinical trials of pharmacological interventions for SARS-CoV-2 published in leading medical journals report adherence but not how it was assessed. |
C. Lee, A. Otunla, I. Brennan, J. K. Aronson, D. Nunan |
| 5 |
[GO] |
2023―Dec―18 |
Feasibility of a cannabidiol (CBD)-dominant cannabis-based medicinal product (CBMP) for the treatment of Long COVID symptoms: A single arm open-label feasibility trial |
Hannah Thurgur, Michael Lynskey, Anne Katrin Schlag, Carol Croser, David John Nutt, Elizabeth Iveson |
| 6 |
[GO] |
2023―Oct―31 |
Adopting human factors in early phase and experimental medicine research: A nested pilot study observing controlled human infection with SARS-CoV-2 |
H. E. Higham, L. Morgan, C. Cooper, J. Marshall, A. Mawer, S. Jackson, R. Lopez Ramon, E. Hughes, D. Richards, H. McShane, J. N. Fullerton |
| 7 |
[GO] |
2023―Oct―25 |
Examining the effectiveness and duration of adjuvanted versus non-adjuvanted influenza vaccines in protecting older adults against symptomatic SARS-CoV-2 infection |
Francesco Lapi, Alexander Domnich, Ettore Marconi, Alessandro Rossi, Ignazio Grattagliano, Claudio Cricelli |
| 8 |
[GO] |
2023―May―24 |
Menstrual abnormalities after COVID-19 vaccination in the Netherlands: a description of spontaneous and longitudinal patient-reported data |
J. W. Duijster, M. E. Schoep, T. E. Nieboer, R. Jajou, A. Kant, F. Van Hunsel |
| 9 |
[GO] |
2023―May―10 |
The impact of the COVID-19 pandemic on antibiotic consumption and prevalence of pathogens in primary and secondary healthcare settings in Northern Ireland |
Mamoon A. Aldeyab, William Crowe, Reema A. Karasneh, Lynsey Patterson, Muhammad Sartaj, Judith Ewing, William J. Lattyak, Sayer Al-Azzam, Mohammad Araydah, Feras Darwish Elhajji, Suad Kabbaha, Barbara R. Conway, Geraldine Conlon-Bingham, David Farren, Michael Scott |
| 10 |
[GO] |
2023―Apr―14 |
Ensovibep, a SARS-CoV-2 antiviral DARPin, is safe and well tolerated in healthy volunteers: results of a first-in-human, ascending single-dose Phase 1 study |
Nina Stojcheva, Stacy Gladman, Marianne Soergel, Christof Zitt, Roxana Drake, Tony Lockett, Carine Marchand, Pierre Fustier, Vaia Stavropoulou, Elena Fernandez, Nathana Lopes Pettigiani, Kate Watkins, Adeep Puri, Randall Watson, Philippe Legenne, Michael Stumpp, Malcolm Boyce |
| 11 |
[GO] |
2023―Feb―15 |
Single dose tocilizumab for COVID-19 associated cytokine storm syndrome: less is more |
Niels W. Boone, Dirk Jan A. R. Moes, Sofia Ramiro, Remy L. M. Mostard, Cesar Magro-Checa, Christel M. P. van Dongen, Michiel Gronenschild, Eric van Haren, Jacqueline Buijs, Annick de Vries, Ralph Peeters, Robert B. M. Landewé, Dennis R. Wong |
| 12 |
[GO] |
2023―Jan―31 |
A case series of Bacillus Calmette-Guérin scar reactivation after administration of both mRNA and viral vector COVID-19 vaccines |
Leontine van Balveren, Eugène P. van Puijenbroek, Linda Davidson, Florence van Hunsel |
| 13 |
[GO] |
2023―Jan―31 |
Efficacy and safety of regdanvimab in patients with mild to moderate COVID-19: A rapid review and meta-analysis |
Behnam Amani, Bahman Amani |
| 14 |
[GO] |
2022―Dec―15 |
Experience with Sotrovimab treatment of SARS-CoV-2 infected patients in Denmark |
Line Dahlerup Rasmussen, Anne-Mette Lebech, Anne Øvrehus, Birgitte Klindt Poulsen, Hanne Rolighed Christensen, Henrik Nielsen, Isik Somuncu Johansen, Lars Haukali Omland, Lothar Wiese, Marie Helleberg, Merete Storgaard, Michael Dalager-Pedersen, Thomas A. Rasmussen, Thomas Benfield, Tonny Studsgaard Petersen, Åse Bengård Andersen, Mie Agermose Gram, Marc Stegger, Sofie Marie Edslev, Niels Obel |
| 15 |
[GO] |
2022―Dec―10 |
Population pharmacokinetics of nadroparin for thromboprophylaxis in COVID-19 ICU patients |
Lorenzo G. R. Romano, Nicole G. M. Hunfeld, Marieke J. H. A. Kruip, Henrik Endeman, Tim Preijers |
| 16 |
[GO] |
2022―Dec―08 |
A Narrative Review of Vaccine Pharmacovigilance During Mass Vaccination Campaigns: Focus on Myocarditis and Pericarditis after COVID-19 mRNA Vaccination |
Pierre-Philippe Piché-Renaud, Shaun K. Morris, Karina A. Top |
| 17 |
[GO] |
2022―Nov―24 |
COVID-19 related medicine utilization study in pregnancy - the COVI-PREG cohort |
Guillaume Favre, Eva Gerbier, Emeline Maisonneuve, Léo Pomar, Ursula Winterfeld, Karine Lepigeon, Kitty W. M. Bloemenkamp, Odette De Bruin, Hurley Eimir, Hedvig Nordeng, Satu J. Siiskonen, Miriam C. J. M. Sturkenboom, David Baud, Alice Panchaud |
| 18 |
[GO] |
2022―Nov―12 |
Management of acquired hemophilia A in severe Covid-19: Hemostatic bridging with emicizumab to keep the balance between bleeding and thrombosis |
Georg Gelbenegger, Ludwig Traby, Nina Rahimi, Paul Knöbl |
| 19 |
[GO] |
2022―Nov―02 |
Communication is Crucial: Lessons from COVID-19 vaccination and pregnancy |
Christine Cole, Maria Tsakiroglou, Catriona Waitt |
| 20 |
[GO] |
2022―Oct―27 |
COVID-19 restrictions and the incidence and prevalence of prescription opioid use in Australia - a nation-wide study |
Monica Jung, Dickson Lukose, Suzanne Nielsen, J. Simon Bell, Geoffrey I. Webb, Jenni Ilomäki |
| 21 |
[GO] |
2022―Oct―10 |
Viral clearance, pharmacokinetics and tolerability of ensovibep in patients with mild to moderate COVID-19 - a phase 2a, open-label, single dose escalation study |
Manon L. M. Prins, Johan L. van der Plas, Maurits F. J. M. Vissers, Cécile L. Berends, Gaby Tresch, Marianne Soergel, Elena Fernández, Nikita van den Berge, Daniël Duijsings, Christof Zitt, Vaia Stavropoulou, Maya Zimmermann, Roxana F. Drake, Jacobus Burggraaf, Geert H. Groeneveld, Ingrid M. C. Kamerling |
| 22 |
[GO] |
2022―Oct―03 |
COVID-19: Clinical status of vaccine development till date |
Sunny Kumar, Malini Basu, Pratyasha Ghosh, Aafreen Ansari, Mrinal K. Ghosh |
| 23 |
[GO] |
2022―Sep―12 |
People exposed to proton pump inhibitors shortly preceding COVID-19 diagnosis are not at an increased risk of subsequent hospitalizations and mortality: a nation-wide matched cohort study |
Ivan Kodvanj, Jan Homolak, Vladimir Trkulja |
| 24 |
[GO] |
2022―Aug―30 |
Comparative assessment of viral dynamic models for SARS-CoV-2 for pharmacodynamic assessment in early treatment trials |
Akosua A. Agyeman, Tao You, Phylinda L. S. Chan, Dagan O. Lonsdale, Christoforos Hadjichrysanthou, Tabitha Mahungu, Emmanuel Q. Wey, David M. Lowe, Marc C. I. Lipman, Judy Breuer, Frank Kloprogge, Joseph F. Standing |
| 25 |
[GO] |
2022―Aug―27 |
Prevalence of NSAID use among people with COVID-19 and the association with COVID-19 related outcomes: systematic review and meta-analysis |
M. D. Huilei Zhao, M. D. Shanshan Huang, M. D. Shan Huang, M. D. Fuwei Liu, B. D. Wen Shao, M. D. Kaibo Mei, M. D. Jianyong Ma, Yuan Jiang, M. D. Jingfeng Wan, M. D. Wengen Zhu, M. D. Peng Yu, M. D. Xiao Liu |
| 26 |
[GO] |
2022―Aug―25 |
Local Variation in Low Carbon Footprint Inhalers in Pre-COVID Pandemic Primary Care Prescribing Guidelines for Adult Asthma in England and its Potential Impact |
Adam J. Twigg, Alexander Wilkinson, James N. Smith |
| 27 |
[GO] |
2022―Aug―12 |
Systemic Exposure to Hydroxychloroquine and its relationship with outcome in severely ill COVID-19 patients in New York City |
Alex K. Lyashchenko, Yifan Yu, Donald J. McMahon, Robert Bies, Michael T. Yin, Serge Cremers |
| 28 |
[GO] |
2022―Jul―20 |
Recombinant protein subunit COVID-19 Vaccine Induced Guillain-Barre Syndrome in an adolescent: A case report |
Rachna Rohilla, Ashish Kumar Kakkar, Krishna Divyashree, Ritin Mohindra, Vikas Suri |
| 29 |
[GO] |
2022―Jul―13 |
Fluvoxamine for COVID-19 outpatients: For the time being, we might prefer to curb our optimism |
Vladimir Trkulja |
| 30 |
[GO] |
2022―Jun―28 |
Rapid Review and Meta-Analysis of Adverse Events Associated with Molnupiravir in Patients with COVID-19 |
Behnam Amani, Sara Zareei, Bahman Amani |
| 31 |
[GO] |
2022―May―28 |
Acute appendicitis in a patient immunised with COVID-19 vaccine: a case report with morphological analysis |
Ettore Marconi, Giada Crescioli, Roberto Bonaiuti, Lavinia Pugliese, Raffaella Santi, Gabriella Nesi, Elisabetta Cerbai, Alfredo Vannacci, Niccolò Lombardi |
| 32 |
[GO] |
2022―Apr―18 |
Erythema nodosum induced by Covid-19 Pfizer-BioNTech mRNA Vaccine: A case report and brief literature review |
Ferdaous Chahed, Najah Ben Fadhel, Haifa Ben Romdhane, Monia Youssef, Seifeddine Ben Hammouda, Amel Chaabane, Karim Aouam, Nadia Ben Fredj |
| 33 |
[GO] |
2022―Apr―16 |
Analgesia and COVID-19 |
William F. Laughey, Imran Lodhi, Olutoba Sanni, Graham Pennick, Bruce Charlesworth |
| 34 |
[GO] |
2022―Mar―31 |
Efficacy of pharmacological interventions in COVID-19: A network meta-analysis |
Sandhiya Selvarajan, Annuja Anandaradje, Santhosh Shivabasappa, Deepthy Melepurakkal Sadanandan, N. Sreekumaran Nair, Melvin George |
| 35 |
[GO] |
2022―Mar―24 |
Cardiovascular drugs and COVID-19 clinical outcomes: a systematic review and meta-analysis of randomized controlled trials |
Innocent G. Asiimwe, Sudeep P. Pushpakom, Richard M. Turner, Ruwanthi Kolamunnage-Dona, Andrea L. Jorgensen, Munir Pirmohamed |
| 36 |
[GO] |
2022―Mar―10 |
Response to Dal-Ré and Holm's ethical concern regarding the UK PANORAMIC COVID-19 trial by the PANORAMIC Investigators |
Christopher C. Butler |
| 37 |
[GO] |
2022―Mar―02 |
Tocilizumab for reduction of mortality in severe COVID-19 patients: How should we GRADE it? |
Vladimir Trkulja |
| 38 |
[GO] |
2022―Feb―22 |
Ethical concern regarding the UK PANORAMIC COVID-19 trial |
Rafael Dal-Ré, Søren Holm |
| 39 |
[GO] |
2022―Feb―17 |
Association study between herpes zoster reporting and mRNA COVID-19 vaccines (BNT162b2 and mRNA-1273) |
Laure-Hélène Préta, Adrien Contejean, Francesco Salvo, Jean-Marc Treluyer, Caroline Charlier, Laurent Chouchana |
| 40 |
[GO] |
2022―Feb―08 |
Fluvoxamine for COVID-19 ICU patients? |
Vladimir Trkulja |
| 41 |
[GO] |
2022―Feb―05 |
Does metformin affect outcomes in COVID-19 patients with new or pre-existing diabetes mellitus? A systematic review and meta-analysis |
Adithan Ganesh, Michael D. Randall |
| 42 |
[GO] |
2022―Feb―02 |
Can nebulised HepArin Reduce morTality and time to Extubation in Patients with COVID-19 Requiring invasive ventilation Meta-Trial (CHARTER-MT): Protocol and Statistical Analysis Plan for an investigator-initiated international meta-trial of prospective randomised clinical studies |
Frank M. P. Haren, John G. Laffey, Antonio Artigas, Clive Page, Marcus J. Schultz, David Cosgrave, Bairbre McNicholas, Thomas L. Smoot, Quentin Nunes, Alice Richardson, Hwan-Jin Yoon, Lex M. Loon, Angajendra Ghosh, Simone Said, Rakshit Panwar, Roger Smith, John D. Santamaria, Barry Dixon |
| 43 |
[GO] |
2022―Jan―11 |
Pharmacokinetic characterization of favipiravir in patients with COVID-19 |
Rezzan Gülhan, Emel Eryüksel, Medine Gülçebi İdriz Oğlu, Yekta Çulpan, Aylin Toplu, Derya Kocakaya, Elif Tigen, Buket Ertürk Şengel, Uluhan Sili, Şehnaz Olgun Yıldızeli, Mehmet Baran Balcan, Abdullah Elçi, Cenk Bulut, Atila Karaalp, Hasan Raci Yananlı, Abdullah Emre Güner, Mustafa Hatipoğlu, Sait Karakurt, Volkan Korten, Neville Ratnaraj, Philip Patsalos, Pınar Ay, Filiz Onat |
| 44 |
[GO] |
2022―Jan―05 |
Inhaled nebulised unfractionated heparin for the treatment of hospitalised patients with COVID-19: A multicentre case series of 98 patients |
Frank M. P. Haren, Lex M. Loon, Anne Steins, Thomas L. Smoot, Caitlin Sas, Sabrina Staas, Alicia B. Vilaseca, Ruben A. Barbera, Gustavo Vidmar, Hugo Beccari, Frida Popilevsky, Eleonora Daribayeva, Bhuvaneshwari Venkatesan, Susan Mozes, Rachel Postel, Natalie Popilevski, Andrew Webb, Quentin Nunes, John G. Laffey, Antonio Artigas, Roger Smith, Barry Dixon, Alice Richardson, Hwan-Jin Yoon, Clive Page |
| 45 |
[GO] |
2021―Dec―29 |
Effects of dalteparin on anti-Xa activities cannot be predicted in critically ill COVID-19 patients |
Charlotte D. C. C. Heijden, Rob Heine, Emma J. Kooistra, Roger J. Brüggemann, Jesper W. J. Walburgh Schmidt, Elke P. L. M. Grouw, Tim Frenzel, Peter Pickkers, Jenneke Leentjens |
| 46 |
[GO] |
2021―Dec―22 |
Association of Renin-Angiotensin-Aldosterone System inhibition with Covid-19 hospitalization and all-cause mortality in the UK Biobank |
Fatemeh Safizadeh, Thi Ngoc Mai Nguyen, Hermann Brenner, Ben Schöttker |
| 47 |
[GO] |
2021―Dec―10 |
Comment on “A case of acute necrotising pancreatitis following the second dose of Pfizer-BioNTech COVID-19 mRNA vaccine” |
Sotaro Ozaka, Takashi Kobayashi, Kazunari Murakami |
| 48 |
[GO] |
2021―Nov―22 |
Coping with COVID: preparing prescribers during the pandemic |
Robin E. Ferner, Julie Mason, Hannah K. Vallance, Tanvi Choudhary, John F. Marriott, Jamie J. Coleman, Sarah K. Pontefract |
| 49 |
[GO] |
2021―Nov―01 |
Safety and efficacy of fluvoxamine in COVID-19 ICU patients: an open label, prospective cohort trial with matched controls |
Martina Calusic, Robert Marcec, Lea Luksa, Ivan Jurkovic, Natasa Kovac, Slobodan Mihaljevic, Robert Likic |
| 50 |
[GO] |
2021―Oct―29 |
Efficacy and safety of tocilizumab versus standard care/placebo in patients with COVID-19; a systematic review and meta-analysis of randomized clinical trials |
Driton Vela, Zana Vela-Gaxha, Mjellma Rexhepi, Rozafa Olloni, Violeta Hyseni, Rajmonda Nallbani |
| 51 |
[GO] |
2021―Sep―24 |
Combination therapies for COVID-19: an overview of the clinical trials landscape |
Sola Akinbolade, Diarmuid Coughlan, Ross Fairbairn, Glenn McConkey, Helen Powell, Dapo Ogunbayo, Dawn Craig |
| 52 |
[GO] |
2021―Sep―12 |
Preparation for the next pandemic-A plea for a nationalized approach |
Adam Cohen |
| 53 |
[GO] |
2021―Aug―23 |
A case of acute necrotising pancreatitis following the second dose of Pfizer-BioNTech COVID-19 mRNA vaccine |
Talia Walter, Saxon Connor, Catherine Stedman, Matthew Doogue |
| 54 |
[GO] |
2021―Aug―19 |
Promoting COVID-19 vaccination through music and drama-Lessons from early phase of the pandemic |
Bernard Appiah, Bhavneet Walia, Su Hyun Nam |
| 55 |
[GO] |
2021―Aug―18 |
Changes in antibiotic prescribing following COVID-19 restrictions: Lessons for post-pandemic antibiotic stewardship |
Malcolm B. Gillies, David P. Burgner, Lorraine Ivancic, Natasha Nassar, Jessica E. Miller, Sheena G. Sullivan, Isobel T. M Todd, Sallie-Anne Pearson, Andrea L. Schaffer, Helga Zoega |
| 56 |
[GO] |
2021―Aug―03 |
Development, evaluation and use of COVID-19 vaccines in older adults: Preliminary principles for the pandemic and beyond |
Sarah N. Hilmer, Mirko Petrovic, David G. Le Couteur, Janice B. Schwartz, Petra Thuermann |
| 57 |
[GO] |
2021―Jul―28 |
COVID-19 Acute Respiratory Distress Syndrome (ARDS): a Simulation Study of the Effects of Combination Therapy with Tocilizumab and Siltuximab |
Eileen B. Doyle, Darren Bentley, Michael G. Dodds |
| 58 |
[GO] |
2021―Jul―23 |
Science fiction has become reality: best practice for future viral pandemics |
Daniel F. B. Wright, Carl M. J. Kirkpatrick |
| 59 |
[GO] |
2021―Jul―17 |
Traditional medicines for COVID-19: Perspectives from clinical pharmacologists |
Getnet Yimer, Edmund Ekuadzi, Pius Fasinu, Andreia Cristina Melo, Goonaseelan (Colin) Pillai |
| 60 |
[GO] |
2021―Jun―26 |
Challenge in treating COVID-19 associate pulmonary aspergillosis: Supratherapeutic voriconazole levels |
Pinar Bakir Ekinci, Emre Kara, Ahmet Gorkem Er, Ahmet Cagkan Inkaya, Kutay Demirkan, Omrum Uzun |
| 61 |
[GO] |
2021―Jun―08 |
Cardiovascular drugs and COVID-19 clinical outcomes: a living systematic review and meta-analysis |
Innocent G. Asiimwe, Sudeep Pushpakom, Richard M. Turner, Ruwanthi Kolamunnage-Dona, Andrea L. Jorgensen, Munir Pirmohamed |
| 62 |
[GO] |
2021―May―15 |
Real life Study on the Pharmacokinetic of Remdesivir in ICU patients admitted for Severe COVID-19 Pneumonia |
Silvia Corcione, Amedeo De Nicolò, Giorgia Montrucchio, Silvia Scabini, Valeria Avataneo, Chiara Bonetto, Simone Mornese Pinna, Jessica Cusato, Francesca Canta, Rosario Urbino, Giovanni Di Perri, Luca Brazzi, Francesco Giuseppe De Rosa, Antonio D'Avolio |
| 63 |
[GO] |
2021―May―13 |
Interferon-α-2b Aerosol Inhalation is Associated with Improved Clinical Outcomes in Patients with Coronavirus Disease-2019 |
Jiong Yu, Xuan Lu, Ling Tong, Xiaowei Shi, Jing Ma, Feifei Lv, Jian Wu, Qiaoling Pan, Jinfeng Yang, Hongcui Cao, Lanjuan Li |
| 64 |
[GO] |
2021―Apr―28 |
Antihypertensive Medications and COVID-19 Diagnosis and Mortality: Population-based Case-Control Analysis in the United Kingdom |
Emma Rezel-Potts, Abdel Douiri, Phil J. Chowienczyk, Martin C. Gulliford |
| 65 |
[GO] |
2021―Apr―26 |
Prior use of therapeutic anticoagulation does not protect against COVID-19 related clinical outcomes in hospitalized patients: a propensity score-matched cohort study |
Janneke P. Spiegelenberg, Marleen M. H. J. Gelder, Martje L. Maas, Marcel M. C. Hovens, Anne Esselink, Anton S. M. Dofferhoff, Rob Janssen, Josephine Maat, Nico Janssen, Marc Blaauw, Robert-Jan Hassing, Marjan Apeldoorn, Angèle Kerckhoffs, Karin Veerman, Jacobien Hoogerwerf, Cornelis Kramers, Jenneke Leentjens |
| 66 |
[GO] |
2021―Apr―23 |
Rethinking the role of Research Ethics Committees in the light of Regulation (EU) No 536/2014 on Clinical Trials and the COVID-19 pandemic |
Silvia Tusino, Maria Furfaro |
| 67 |
[GO] |
2021―Apr―23 |
Ethics of vaccination: should capability measures be used to inform SARS-CoV-2 vaccination strategies
? |
Michael R. Millar, Yannis Gourtsoyannis, Angelina Jayakumar |
| 68 |
[GO] |
2021―Apr―15 |
Economic evaluation of remdesivir for the treatment of severe COVID-19 patients in China under different scenarios |
Yawen Jiang, Dan Cai, Daqin Chen, Shan Jiang, Lei Si, Jing Wu |
| 69 |
[GO] |
2021―Apr―15 |
BLUEPRINT FOR PANDEMIC RESPONSE: FOCUS ON TRANSLATIONAL MEDICINE, CLINICAL PHARMACOLOGY, AND PHARMACOMETRICS |
Jasmine Davda, Kellie Reynolds, John D. Davis, Patrick F. Smith |
| 70 |
[GO] |
2021―Apr―13 |
SARS-CoV-2 mutations: A strain on efficacy of neutralizing monoclonal antibodies? |
Marko Boskovic, William Migo, Robert Likic |
| 71 |
[GO] |
2021―Mar―25 |
Liver and kidney function in patients with Covid-19 treated with remdesivir |
Sylvia A. Laar, Mark G. J. Boer, Kim B. Gombert-Handoko, Henk-Jan Guchelaar, Juliette Zwaveling |
| 72 |
[GO] |
2021―Mar―24 |
Will AstraZeneca be able to provide clinical trial data on its COVID-19 vaccine efficacy in older adults? |
Rafael Dal-Ré |
| 73 |
[GO] |
2021―Mar―20 |
Zinc supplementation as an adjunct therapy for COVID-19: challenges and opportunities |
Vidyasagar Chinni, Hanna El-Khoury, Marlon Perera, Rinaldo Bellomo, Daryl Jones, Damien Bolton, Joseph Ischia, Oneel Patel |
| 74 |
[GO] |
2021―Mar―09 |
Intestinal SGLT1 as a therapeutic target in COVID-19-related diabetes: A “two-edged sword” hypothesis |
Theocharis Koufakis, Symeon Metallidis, Pantelis Zebekakis, Kalliopi Kotsa |
| 75 |
[GO] |
2021―Feb―20 |
Dexamethasone use and Mortality in Hospitalized Patients with Coronavirus Disease 2019: a Multicenter Retrospective Observational Study |
Nicolas Hoertel, Marina Sánchez-Rico, Raphaël Vernet, Nathanaël Beeker, Antoine Neuraz, Jesús M. Alvarado, Christel Daniel, Nicolas Paris, Alexandre Gramfort, Guillaume Lemaitre, Elisa Salamanca, Mélodie Bernaux, Ali Bellamine, Anita Burgun, Frédéric Limosin |
| 76 |
[GO] |
2021―Feb―20 |
Repurposing of thalidomide and its derivatives for the treatment of SARS-coV-2 infections: Hints on molecular action |
Lakshmikirupa Sunderesan, Suvendu Giri, Himanshi Singh, Suvro Chatterjee |
| 77 |
[GO] |
2021―Feb―13 |
Postvaccination anaphylaxis and mRNA-based SARS-CoV-2 vaccines-Much ado about nothing? |
Robert Marcec, Robert Likic |
| 78 |
[GO] |
2021―Jan―28 |
No association between use of ACE inhibitors or angiotensin II receptor blockers prior to hospital admission and clinical course of COVID-19 in the COvid MEdicaTion (COMET) study |
Roos S.G. Sablerolles, Freija E.F. Hogenhuis, Melvin Lafeber, Bob P.A. Loo, Sander D. Borgsteede, Eric Boersma, Jorie Versmissen, Hugo Kuy |
| 79 |
[GO] |
2020―Dec―30 |
INHALEd nebulised unfractionated HEParin for the treatment of hospitalised patients with COVID-19 (INHALE-HEP): Protocol and Statistical Analysis Plan for an investigator-initiated international meta-trial of randomised studies |
Frank M.P. Haren, Alice Richardson, Hwan-Jin Yoon, Antonio Artigas, John G. Laffey, Barry Dixon, Roger Smith, Alicia B. Vilaseca, Ruben A. Barbera, Tarek I. Ismail, Rabab S. Mahrous, Mohamed Badr, Gilberto DeNucci, Carlos Sverdloff, Lex M. Loon, Marta Camprubi-Rimblas, David W. Cosgrave, Thomas L. Smoot, Sabrina Staas, Khine Sann, Caitlin Sas, Anusha Belani, Christopher Hillman, Janis Shute, Mary Carroll, Tom Wilkinson, Miles Carroll, Dave Singh, Clive Page |
| 80 |
[GO] |
2020―Dec―30 |
Using in silico viral kinetic models to guide therapeutic strategies during a pandemic: An example in SARS-CoV-2 |
Kashyap Patel, Michael Dodds, Antonio Gonçalves, Mohamed A. Kamal, Craig R. Rayner, Carl M. Kirkpatrick, Patrick F. Smith |
| 81 |
[GO] |
2020―Dec―18 |
A possible increased risk of metamizole-associated neutropenia among COVID-19 patients |
Tsahi T. Lerman, Moshe Sagi, Yair Shafir, Liron Sheena, Eytan Cohen, Elad Goldberg, Ilan Krause |
| 82 |
[GO] |
2020―Dec―02 |
Racing to immunity: Journey to a COVID-19 vaccine and lessons for the future |
Ester Calvo Fernández, Lucie Y. Zhu |
| 83 |
[GO] |
2020―Nov―27 |
Clinical studies assessing the efficacy, effectiveness, and safety of remdesivir in management of COVID-19: a scoping review |
Juan Pimentel, Cassandra Laurie, Anne Cockcroft, Neil Andersson |
| 84 |
[GO] |
2020―Nov―24 |
Pharmacokinetics under the COVID-19 Storm |
Venkatesh Pilla Reddy, Eman El-Khateeb, Heeseung Jo, Natalie Giovino, Emily Lythgoe, Shringi Sharma, Weifeng Tang, Masoud Jamei, Amin Rastomi-Hodjegan |
| 85 |
[GO] |
2020―Nov―21 |
Chasing COVID-19 chemotherapeutics without putting the cart before the horse |
Steven P. Rannard, Tom O. McDonald, Andrew Owen |
| 86 |
[GO] |
2020―Nov―21 |
Comparison of Infection Risks and Clinical Outcomes in Patients with and without SARS-CoV-2 Lung Infection under Renin-Angiotensin-Aldosterone-System Blockade - Systematic Review and Meta-Analysis |
Chang Chu, Shufei Zeng, Ahmed A. Hasan, Carl-Friedrich Hocher, Bernhard K. Kraemer, Berthold Hocher |
| 87 |
[GO] |
2020―Nov―13 |
Olfactory and gustatory impairments in COVID-19 patients: Role in early diagnosis and interferences by concomitant drugs |
Sara Ferraro, Marco Tuccori, Irma Convertino, Giulia Valdiserra, Emiliano Cappello, Fabrizio Maggi, Corrado Blandizzi, Daniele Focosi |
| 88 |
[GO] |
2020―Oct―30 |
Risk Assessment of therapeutic agents under consideration to treat COVID-19 in Pediatric Patients and Pregnant Women |
Jeffrey S. Barrett |
| 89 |
[GO] |
2020―Oct―29 |
Challenges of drug development during the COVID-19 pandemic: key considerations for clinical trial designs |
Jun Shi, Yubo Xiao, Yiting Zhang, Donghao Geng, Danhua Cong, Kevin X. Shi, Richard J. Knapp |
| 90 |
[GO] |
2020―Oct―24 |
Hospitalization for COVID-19 in patients treated with selected immunosuppressant and immunomodulating agents, compared to the general population - a Danish cohort study |
Bente Mertz Nørgård, Jan Nielsen, Torben Knudsen, Rasmus Gaardskær Nielsen, Michael Due Larsen, Line Riis Jølving, Jens Kjeldsen |
| 91 |
[GO] |
2020―Oct―21 |
Dose Prediction for Repurposing Nitazoxanide in SARS-CoV-2 Treatment or Chemoprophylaxis |
Rajith K.R. Rajoli, Henry Pertinez, Usman Arshad, Helen Box, Lee Tatham, Paul Curley, Megan Neary, Joanne Sharp, Neill J. Liptrott, Anthony Valentijn, Christopher David, Steven P. Rannard, Ghaith Aljayyoussi, Shaun H. Pennington, Andrew Hill, Marta Boffito, Steve A. Ward, Saye H. Khoo, Patrick G. Bray, Paul M. O'Neill, W. David Hong, Giancarlo Biagini, Andrew Owen |
| 92 |
[GO] |
2020―Oct―14 |
COVID-19 vaccines: the importance of transparency and fact-based education |
Adam F. Cohen, Joop Gerven, Juan Garcia Burgos, Anthonius Boer, Ron A. M. Foucher, H. Flore, Zvi Teitelbaum, Willem Eden, Andrew Webb, Serge Cremers |
| 93 |
[GO] |
2020―Oct―13 |
Efficacy and safety outcomes of proposed randomized controlled trials investigating hydroxychloroquine and chloroquine during the early stages of the COVID-19 pandemic |
Daniela R. Junqueira, Brian H. Rowe |
| 94 |
[GO] |
2020―Sep―22 |
A PHARMACOLOGICAL FRAMEWORK FOR INTEGRATING TREATING THE HOST, REPURPOSING AND THE DAMAGE RESPONSE FRAMEWORK IN COVID-19 |
Jennifer Martin, Richard Head |
| 95 |
[GO] |
2020―Sep―03 |
Beyond Dexamethasone, Emerging Immuno-Thrombotic Therapies for COVID-19 |
Melanie Peta Jensen, Marc George, Derek Gilroy, Reecha Sofat |
| 96 |
[GO] |
2020―Aug―31 |
Supporting frontline clinicians in the time of the pandemic: Rapid response pharmacology team |
Karin B. Mirzaev, Yury Kiselev, Dmitriy V. Ivashchenko, Vitaly Otdelenov, Dmitry A. Sychev |
| 97 |
[GO] |
2020―Aug―25 |
Lessons for teaching from the pandemic |
Jan Strojil, Hana Suchánková |
| 98 |
[GO] |
2020―Aug―21 |
Prescribing in COVID-19 patients: Should we take into account inflammation? |
Catia Marzolini, Manuel Battegay, Parham Sendi, David J. Back |
| 99 |
[GO] |
2020―Aug―17 |
The COVID-19 Ibuprofen controversy; a systematic review of NSAIDs in adult acute lower respiratory tract infections |
Ricky Vaja, Jeffery Chan, Plinio Ferreira, Amer Harky, Luke J. Rogers, Hime H. Gashaw, Nicholas S. Kirkby, Jane A. Mitchell |
| 100 |
[GO] |
2020―Jul―21 |
ABNORMAL LABORATORY FINDINGS AND PLASMA CONCENTRATION MONITORING OF LOPINAVIR AND RITONAVIR IN COVID-19 |
Benjamin Batteux, Sandra Bodeau, Valérie Gras-Champel, Sophie Liabeuf, Jean-Philippe Lanoix, Jean-Luc Schmit, Claire Andréjak, Yoann Zerbib, Guillaume Haye, Kamel Masmoudi, Anne-Sophie Lemaire-Hurtel, Youssef Bennis |
| 101 |
[GO] |
2020―Jul―21 |
Model-Informed Drug Repurposing: Viral Kinetic Modeling to Prioritize Rational Drug Combinations for COVID-19 |
Michael G. Dodds, Rajesh Krishna, Antonio Goncalves, Craig R. Rayner |
| 102 |
[GO] |
2020―Jul―18 |
Pharmacokinetic considerations on the repurposing of ivermectin for treatment of COVID-19 |
Ricardo Peña-Silva, Stephen B. Duffull, Andrew C. Steer, Sandra X. Jaramillo-Rincon, Amanda Gwee, Xiao Zhu |
| 103 |
[GO] |
2020―Jul―15 |
The impact of the global COVID-19 pandemic on the conduct of clinical trials. Return to normalcy by considering the practical impact of a structured ethical analysis |
Maurits F.J.M. Vissers, Adam F. Cohen, Joop M.A. Gerven, Geert Jan Groeneveld |
| 104 |
[GO] |
2020―Jul―13 |
Insights from compassionate use of tocilizumab for COVID-19 to inform appropriate design of randomised controlled trials |
Emma H. Baker, Kamal Patel, Jonathan Ball, Sarah Edwards, Thomas S. Harrison, Arvind Kaul, Mickey Koh, Sanjeev Krishna, Susannah Leaver, Vinodh Kumar, Daniel M. Forton |
| 105 |
[GO] |
2020―Jul―08 |
Serious adverse events with tocilizumab: pharmacovigilance as an aid to prioritize monitoring in COVID-19 |
Milo Gatti, Michele Fusaroli, Paolo Caraceni, Elisabetta Poluzzi, Fabrizio De Ponti, Emanuel Raschi |
| 106 |
[GO] |
2020―Jul―06 |
Potential role of IL-17 blocking agents in the treatment of severe COVID-19? |
Vedrana Bulat, Mirna Situm, Marija Delas Azdajic, Robert Likic |
| 107 |
[GO] |
2020―Jun―19 |
Model informed dosing of Hydroxycholoroquine in COVID-19 patients: Learnings from the recent experience, remaining uncertainties and Gaps |
Pauline Thémans, Nicolas Dauby, Loïc Schrooyen, Faustine Lebout, Marc Delforge, Rakan Nasreddine, Agnès Libois, Marie-Christine Payen, Déborah Konopnicki, Francoise Wuillaume, Cecile Lescrainier, Veerle Verlinden, Jean-Michel Dogné, Jamila Hamdani, Flora T. Musuamba |
| 108 |
[GO] |
2020―Jun―19 |
How to expedite early phase SARS-CoV-2 vaccine trials in pandemic setting - a practical perspective |
J.L. Plas, M. Roestenberg, A.F. Cohen, I.M.C. Kamerling |
| 109 |
[GO] |
2020―Jun―09 |
A call for the appropriate application of clinical pharmacological principles in the search for safe and efficacious COVID-19 (SARS-COV-2) treatments |
Emma H. Baker, Danijela Gnjidic, Carl M.J. Kirkpatrick, Munir Pirmohamed, Daniel F.B. Wright, Anna Y. Zecharia |
| 110 |
[GO] |
2020―May―08 |
Chronic myeloid leukemia and the use of tyrosine kinase inhibitors in the days of COVID-19 pandemic |
Ahmet Emre Eşkazan |
| 111 |
[GO] |
2020―May―08 |
COVID-19 treatment in patients with comorbidities: Awareness of drug-drug interactions |
David Back, Catia Marzolini, Catherine Hodge, Fiona Marra, Alison Boyle, Sara Gibbons, David Burger, Saye Khoo |
| 112 |
[GO] |
2020―May―02 |
Off-target ACE2 ligands: possible therapeutic option for CoVid-19? |
Simone Brogi, Vincenzo Calderone |
| 113 |
[GO] |
2020―Apr―30 |
COVID-19 and (hydroxy)chloroquine-Azithromycin combination: Should we take the risk for our patients? |
Hervé Javelot, Wissam El-Hage, Guillaume Meyer, Guillaume Becker, Bruno Michel, Coraline Hingray |
| 114 |
[GO] |
2020―Apr―18 |
Dosing will be a key success factor in repurposing antivirals for COVID-19 |
Patrick F. Smith, Michael Dodds, Darren Bentley, Karen Yeo, Craig Rayner |
|
